UCB today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion to approve marketing authorisation of Keppra® (levetiracetam) as monotherapy in the treatment of p...

Several new antiepileptic drugs (AEDs) are effective in treating selected patients with partial or mixed seizure disorders, but evidence for their efficacy in patients with generalized epilepsy syndromes is lacking, according to a meta-analysis by the American Academy...

Approval for Intravenous Administration ...

The American Academy of Neurology (AAN) has released evidence-based guidelines for prescribing new antiepileptic drugs (AEDs) in patients with new-onset epilepsy and refractory epilepsy. The recommendations, "Efficacy and Tolerability of the New Antiepileptic Dru...

The antiepileptic drug Keppra® (levetiracetam), when used alone and in combination with other treatments, improved symptoms in approximately half of children and adult patients with either bipolar or aggressive disorders, according to two new studies presented to...

EC approves new indication for Keppra® as adjunctive therapy in the treatment of primary generalised tonic-clonic seizures in patients with Idiopathic Generalised Epilepsy ...

Keppra® now approved to treat a generalized seizure type in adult and adolescent patients ...

Significant advances have been made in the diagnosis and treatment of epilepsy over the past decade. With the advent of electroencephalographic video monitoring, physicians are now able to reliably differentiate epilepsy from other conditions that can mimic it, such a...

The American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society have released a report on treatment of migraine headache in children and adolescents. "Practice Parameter: Pharmacological Treatment of Migr...

030 Preoperative Heat Shock Modifies Liver Injury and Regeneration in Mice after 70% Partial Hepatectomy. NOBUYA ISHIBASHI, MD, PhD, Yousuke Oka, MD, Roman Safranek, MD, Nobutaka Iwakuma, MD, Hiroyuki Ozasa, MD, Satoru Ikeda, MD, Kazuo Shirouzu, MD, PhD. Department of...

Introduction: Medications are the primary treatment for epilepsy, yet many teens and their families have problems managing seizure medicines. Fear of side effects, difficulties remembering to take medicines and figuring out how to take them are common challenges....

Abstract This case study documents the use of a ketogenic diet for the treatment of intractable seizures in a previously healthy 32-year-old man. Although the use of the diet for children is well-documented, it is less common in adults. A carbohydrate-free fee...

The FDA granted an additional indication for Keppra (levetiracetam), manufactured by UCB (Brussels, Belgium), as an adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. Ke...

Business Editors & Health/Medical Writers BIOWIRE2K GAITHERSBURG, Md. & CAMBRIDGE, Mass.--(BW HealthWire)--Sept. 6, 2001 -- UCB UCB - Ultraviolet Coronal BerkeleyUCB - Unemployment Compensation BenefitsUCB - Unit Control BlockUCB - United Carolina BankUCB...

There are billions of nerve cells in the human brain that communicate through electrical charges or signals. These signals can travel from the brain to various body parts to control muscle movements or transmit sensory information. Many of the brain signals trave...

FDA listed the following drugs and drug products as having had modifications to the Contraindications and/or Warnings/Boxed Warnings sections. For additional information or to read the full labeling of the drug products, visit: http://www.fda.gov/medwatch/ Agg...

Tokyo, Japan, Aug 14, 2006 - (JCN) - UCB Japan, a leading global biopharmaceutical company has obtained the approval of Keppra - generic name levetiracetam levetiracetam /le·ve·ti·rac·e·tam/ (le?ve-ti-ras´e-tam) an anticonvulsant used in the treatment of p...

Abstract: Ongoing refinements in pharmacology continue to provide new medications for the treatment of seizure disorders and other neurologic conditions. The authors present the cases of two children who developed relatively uncommon adverse effects to new antico...